Clinical Trial Update: Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery [Phase 2]

View source ↗

Summary

This report notes the completion of a Phase 2 trial evaluating TB-402 for the prevention of venous thromboembolism after total knee replacement surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• TB-402

Snippet

Sponsor: ThromboGenics | Conditions: Total Knee Replacement Surgery | Phase 2 | Status: COMPLETED